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primary insomnia and the relative risk of the health consequence
in persons with versus without insomnia. Based on published
sources, we estimated the prevalence of chronic primary insom-
nia to be 2.3% and relative risks to be as follows: car crashes,
2.5; work accidents, 1.5; home/public accidents, 2.5; alcohol
abuse, 2.3; illicit drug abuse, 1.9; nicotine dependency, 2.4; and
depression, 5.4. RESULTS: Total annual societal cost of chronic
primary insomnia in the U.S. was estimated to be US$24.6 billion
in 2003. Depression accounted for the largest share of the cost
burden (34%), followed by alcohol abuse (25%), nicotine depen-
dency (20%), drug abuse (14%), work loss (6%), accidental
injuries (2%), and prescription insomnia medications (1%). Sen-
sitivity analysis indicated the ﬁndings were most sensitive to the
prevalence of chronic primary insomnia and the relative risk of
illicit drug abuse. CONCLUSIONS: The economic burden of
chronic primary insomnia is substantial. Reducing the severity
and prevalence of chronic primary insomnia may yield consid-
erable economic beneﬁts.
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OBJECTIVES: To estimate the direct healthcare cost burden of
migraine in a large commercially insured United States (US) pop-
ulation. METHODS: The data source for this study was the
MEDSTAT MarketScan database, comprised of medical, phar-
maceutical, and enrollment information on employees for 52
employer groups for the calendar year 2004. Subjects with a
diagnosis of migraine or use of a migraine-speciﬁc abortive drug
were identiﬁed as the migraine cohort. A random sample of
patients without migraine was propensity score matched, based
on demographic characteristics and comorbidity index, to the
migraine cohort to yield a matched control group. Expenditures
between migraine and matched control cohorts were compared
to derive the burden of illness attributable to migraine.
RESULTS: The analyses included 215,209 subjects in the
migraine cohort, and equal number of subjects in the control
group. The mean age was 41 (SD = 13.3), and 82% were female.
After matching, the cohorts were similar with respect to age,
gender, geographic region, urban residence, insurance type, the
number of psychiatric diagnostic groups and Charlson comor-
bidity index. The migraine cohort incurred signiﬁcantly higher
expenditure than the control cohort in all categories (prescrip-
tions, outpatient, ER, and inpatient). Total health care expendi-
tures were $2571 per patient per year (PPPY) higher in the
migraine group ($7007 versus $4436 PPPY in the control group;
p < 0.001). CONCLUSIONS: The migraine cohort was associ-
ated with signiﬁcantly higher total health care expenditures com-
pared to a matched control, based on recent data from a large
sample of commercially insured individuals. This data suggest
that US employers are bearing a considerable direct cost burden
as a consequence of migraine.
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OBJECTIVES: Although studies have explored the utilization of
healthcare services in patients with restless leg syndrome (RLS),
expenditure data are not available. This study assesses the incre-
mental economic burden of illness with RLS. METHODS: A 
retrospective claims database analysis was conducted using
Medstat’s MarketScan Commercial Claims and Encounters data-
base from 1999 through 2003. Patients were identiﬁed having 
≥ 1 RLS diagnosis (ICD-9 333.99) with the earliest claim as the
index event. Inclusion criteria required continuous enrollment 6
months pre- and 12 months post-index event. Patients were
excluded if they were identiﬁed as having Parkinson’s disease,
post-traumatic neurosurgery, or psychiatric conditions (other
than depression and insomnia); or if they had a drug claim in
the pre-index period for levodopa, dopamine agonists, opioids,
anticonvulsants, amantadine or clonidine. A control group
without a diagnosis for RLS and similar inclusion/exclusion cri-
teria as the RLS group was selected using a 1 :1 propensity score
match. Post-index outcomes included health care utilization and
expenditures (2003 dollars), along with multivariate analysis
used to determine the incremental economic burden associated
with RLS. RESULTS: The RLS group consisted of 2319 patients
with an average age of 49.8 years and was 64% female. In the
post-index period, RLS patients had higher total expenditures
than controls ($8843 vs $4378), with highest costs from outpa-
tient services ($4549 vs $2144, respectively). In the multivariate
analysis, the incremental difference in overall expenditures
between the RLS cohort ($7257) and controls ($4809) was
$2448 (p < 0.001). CONCLUSIONS: Expenditures for RLS
treated patients are signiﬁcantly higher when compared to a
matched, control cohort of patients, with the highest costs
coming from outpatient services. More research is warranted to
identify if there are ways to decrease these additional costs while
maintaining or improving treatment of patients with RLS.
PNL20
HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE
SCLEROSIS IN A COMMERCIAL MANAGED CARE
ENVIRONMENT
Prescott J
The MCM Group, Marlton, NJ, USA
OBJECTIVES: Benchmark direct health care costs and utiliza-
tion for patients with multiple sclerosis (MS) in a commercial
managed care environment. Observe how demographic, admin-
istrative, and clinical variables affect MS costs and utilization
patterns. Examine the economic impact of treating MS with
disease modifying drugs (DMDs). METHODS: Using a propri-
etary methodology developed by the MCM Group, administra-
tive claims data (obtained from the PharMetrics Integrated
Patient-centric Database) were combined with Symmetry
Health’s Episode Treatment GroupTM (ETGTM) illness-classiﬁca-
tion and episode-building software. Patients were included in the
study based on the presence of ETGs 149 or 150 (inﬂammation
of the CNS) and diagnosis of MS (ICD-9 code 340.*) during any
of calendar years 2002, 2003, or 2004. Clinical and economic
information related to utilization of medical and pharmacy ser-
vices was captured using ETG-deﬁned episodes of care, consist-
ing of observations made over 365 days. RESULTS: Over the
3-year study period, 41,425 patient-episodes were analyzed, with
10,099 analyzed for 2004. Total costs of a 2004 MS episode
were $12,879, 65% of which were attributable to prescription
drugs and more than 26% to outpatient care. Many variables
affected episode costs, including concurrent conditions; for
example, episode costs increased considerably whenever abnor-
mality of gait ($20,871) or optic neuritis ($39,247) was present.
In comparing episodes reporting use of DMDs, the various inter-
feron product classes and other immunomodulators reﬂected
